Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases

US11427590B2 · kind B2 · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• Institute of Organic Chemistry & Biochemistry · CZ

Inventors

• Barbara Slusher · Kingsville, US
• Camilo Rojas · Baltimore, US
• Ajit G. Thomas · Baltimore, US
• Radim Nencka · Praha, CZ
• Michal Sala · Kladno, CZ
• Hubert Hrebabecky · Praha, CZ
• Norman Haughey · Baltimore, US

Key dates

• Filing date: Jan 5, 2018
• Grant date: Aug 30, 2022
• Expiry date: Jan 5, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.